Entecavir: A potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 5, 2008, Pages 569-579

  Cheng, Pin Nan ^a   Chang, Ting Tsung ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ALT; Chronic hepatitis B; Cirrhosis; HBeAg; HBV DNA; Hepatocellular carcinoma; Lamivudine refractory; Lamivudine refractory resistance; Nucleoside naive patients; Resistance; Seroconversion; Viral suppression

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CLEVUDINE; CYCLOSPORIN; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PLACEBO; TACROLIMUS; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARCINOGENICITY; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; LIVER GRAFT REJECTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; POSTMARKETING SURVEILLANCE; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 55249118410     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.5.569     Document Type: Article

References (52)

1. Chen CJ, Yang HI, Su J et al. REVEAL-HBV Study Group: risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
2. Chen CJ, Yang HI, Su J et al. Impact of chronically elevated HBV DNA viral load on risk of HCC occurrence: an update from the R.E.V.E.A.L-HBV Study. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A208-A209 (2008) (Abstract PE1015).
3. Chen CF, Yang HI, Iloeje UH et al. Changes in serum HBV-DNA level using a trajectory model to predict the risk of HCC in chronic hepatitis B patients: the R.E.V.E.A.L-HBV Study. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study ofthe Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A188 (2008) (Abstract FP135).
4. 4 copies/ml is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L-HBV study. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A187-A188 (2008) (Abstract FP133).
5. AASLD Practice Guidelines. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45 (2), 507-539 (2007).
6. APASL Consensus Statement. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 25(3), 472-489 (2005).
7. US HBV Treatment Algorithm. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 4(8), 936-962 (2006).
8. Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54(11), 1610-1614 (2005).
9. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon a treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34(1), 139-145 (2001).
10. Zhu Y, Yamamoto T et al. Kinetics of Hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75(1), 311-322 (2001).
11. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341(17), 1256-1263 (1999).
12. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339(2), 61-68 (1998).
13. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and a interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46(4), 562-568 (2000).
14. Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19(11), 1276-1282 (2004).
15. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6), 1714-1722 (2003).
16. Manns M, Jeffers L, Dalekos G et al. The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB). Presented at: the 43rd Annual Conference of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23-26 March 2008. J. Hepatol. 48(S1), s33 (2008) (Abstract 74).
17. Heathcote J, George J, Gordon S et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 103). Presented at: the 43rd Annual Conference of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23-26 March 2008. J. Hepatol. 48 (S1), s32 (2008) (Abstract 72).
18. Marcellin P, Jacobson I, Habersetzer F et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 102). Presented at: the 43rd Annual Conference of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23-26 March 2008. J. Hepatol. 48(SI), s26 (2008) (Abstract 57).
19. Bisacchi GS, Chao ST, Bachard C et al. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro. Bioorg. Med. Chem. Lett. 7(2), 127-132 (1997).
20. Domaoal RA, McMahon M, Thio CL et al. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem. 283(9), 5452-5459 (2008).
21. Yamanaka G, Wilson T, Innaimo S et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. 43(1), 190-193 (1999).
22. Innaimo SF, Seifer M, Bisacchi GS et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41(7), 1444-1448 (1997).
23. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42(12), 3200-3208 (1998).
24. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51(3), 902-911 (2007).
25. Baldick CJ, Tenney DJ, Mazzucco CE et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 47(5), 1473-1482 (2008).
26. McMahon MA, Jilek BL, Brennan, TP et al. Drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356(25), 2614-2621 (2007)
27. Sasadeusz J, Audsley J, Mijch A et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 22 (8), 947-955 (2008).
28. Lin PF, Nowicka-Sans B, Terry B et al. entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob. Agents. Chemother. 52(5), 1759-1767 (2008).
29. Colonno RJ, Genovesi EV, Medina I et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 184(10), 1236-1245 (2001).
30. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. 46(1), 82-88 (2002).
31. Genovesi EV, Lamb L, Medina I et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42(12), 3209-3217 (1998).
32. Foster WK, Miller DS, Marion PL et al. entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob. Agents Chemother. 47(8), 2624-2635 (2003).
33. de Man RA, Wolters LM, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34(3), 578-582 (2001).
34. Lai CL, Rosmawati M, Lao J et al. entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123(6), 1831-1838 (2002).
35. Chang TT, Gish RG, Hadziyannis SJ et al. BEHoLD Study Group. A dose-ranging study of the cfficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129(4), 1198-1209 (2005)
36. Chang TT, Gish RG, de Man R et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N. Engl. J. Med. 354(10), 1001-1010 (2006).
37. Gish RG, Lok AS, Chang TT et al. entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133(5), 1437-1444 (2007).
38. Chang TT, Chao YC, Yoon SK et al. Four-year treatment with entecavir results in high proportions of nucleoside-naive HBeAg-positive patients with undetectable HBV DNA: results from studies ETV-022 and -901. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A111-A112 (2008) (Abstract FP001).
39. Lai CL, Shouval D, Lok AS et al. BEHoLD AI463027 study group. entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011-1020 (2006). Erratum in N. Engl. J. Med. 354(17), 1863 (2006).
40. Sherman M, Yurdaydin C, Sollano J et al. AI463026 BEHoLD study group. entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130(7), 2039-2049 (2006).
41. Sherman M, Yurdaydin C, Simsek H et al. entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48, 99-108 (2008).
42. + antiviral-naive adults: 48-week results (E.A.R.L.Y. study). Presented at the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL). Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A113-A114 (2008) (Abstract FP007).
43. Chang TT, Lai CL, Han S et al. Efficacy of entecavir in nucleoside-naïve patients with mildly elevated ALT. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A223-A224 (2008) (Abstract PE1070).
44. Simsek H, Schiff E, Goodman Z et al. Efficacy of entecavir and lamivudine in chronic hepatitis b patients with advanced liver fibrosis/ cirrhosis. Presented at: the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23-26 March 2008. J. Hepatol. 46(S1), S197 (2008) (Abstract 518).
45. Wong DK, Yuen MF, Ngai V et al. One-Year treatment of entecavir results in reduction in intrahepatic covalently closed circular DNA level. Presented at: the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, USA, 11-15 November 2005. Hepatology 42 (4 Suppl. 1) A573 (2005) (Abstract 960).
46. Colonno RJ, Rose R, Baldick CJ et al. entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6), 1656-1665 (2006).
47. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51(3), 902-911 (2007).
48. Tenney DJ, Pokomowski KA, Rose RE et al. entecavir at five years shows long-term maintenance of high genetic barrier to Hepatitis B virus resistance. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A88-A89 (2008) (Abstract PL02).
49. Yokosuka O, Kumada H, Toyota J et al. Three year assessment of entecavir (ETV) resistance in nucleoside-naive and lamivudine (LVD) refractory Japanese patients with chronic hepatitis B (CHB). Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23-26 March 2008. Hepatol. Int. 2, A161 (2008) (Abstract FP067).
50. + chronic hepatitis B patients (ETV-026). Gastroenterology 130(4 Suppl. 2), 765 (2006) (Abstract 478).
51. Poordad F, Dietrich DT, Min AD et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg chronic hepatitis B patients (STUDY ETV-027). Gastroenterology 130(4 Suppl. 2), 848 (2006) (Abstract T1851).
52. Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs 66(12), 1605-1622; discussion 1623-1624 (2006).